IMCR
Closed
Immunocore Holdings Ltd
32.84
+1.46 (+4.65%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 31.38
Day's Range: 31.37 - 33.72
Send
sign up or login to leave a comment!
When Written:
49.56
Immunocore Holdings Ltd is a biotechnology company that focuses on the development of T-cell receptor (TCR) based therapies for the treatment of cancer, infectious diseases, and autoimmune disorders. The company was founded in 2008 and is headquartered in Oxfordshire, UK.
Immunocore's proprietary technology platform is based on the use of TCRs, which are naturally occurring proteins found on the surface of T-cells. These TCRs can recognize and bind to specific antigens, which are molecules that are present on the surface of cancer cells, infectious agents, or diseased cells.
Immunocore's lead product candidate is IMCgp100, a TCR-based therapy for the treatment of melanoma. The company has also developed a pipeline of other TCR-based therapies for various types of cancer, including liver cancer, bladder cancer, and lung cancer.
Immunocore has partnerships with several pharmaceutical companies, including AstraZeneca, Genentech, and Eli Lilly, to develop and commercialize its TCR-based therapies. The company has raised over $1 billion in funding from investors, including the Bill and Melinda Gates Foundation, and is considered one of the leading companies in the field of TCR-based therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Immunocore's proprietary technology platform is based on the use of TCRs, which are naturally occurring proteins found on the surface of T-cells. These TCRs can recognize and bind to specific antigens, which are molecules that are present on the surface of cancer cells, infectious agents, or diseased cells.
Immunocore's lead product candidate is IMCgp100, a TCR-based therapy for the treatment of melanoma. The company has also developed a pipeline of other TCR-based therapies for various types of cancer, including liver cancer, bladder cancer, and lung cancer.
Immunocore has partnerships with several pharmaceutical companies, including AstraZeneca, Genentech, and Eli Lilly, to develop and commercialize its TCR-based therapies. The company has raised over $1 billion in funding from investors, including the Bill and Melinda Gates Foundation, and is considered one of the leading companies in the field of TCR-based therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!